Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy

Epithelial ovarian cancer (EOC) ranks as the second most common cause of gynecologic cancer death. The conventional treatment for patients with EOC is postoperative therapy along with platinum chemotherapy. However, a more efficient treatment regimen is of great need for these patients diagnosed wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yusha, Zhang, Lei, Bai, Yun, Wang, Li, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630909/
https://www.ncbi.nlm.nih.gov/pubmed/36341388
http://dx.doi.org/10.3389/fimmu.2022.1036298
_version_ 1784823710000087040
author Wang, Yusha
Zhang, Lei
Bai, Yun
Wang, Li
Ma, Xuelei
author_facet Wang, Yusha
Zhang, Lei
Bai, Yun
Wang, Li
Ma, Xuelei
author_sort Wang, Yusha
collection PubMed
description Epithelial ovarian cancer (EOC) ranks as the second most common cause of gynecologic cancer death. The conventional treatment for patients with EOC is postoperative therapy along with platinum chemotherapy. However, a more efficient treatment regimen is of great need for these patients diagnosed with advanced disease (FIGO stages III–IV), whose survival is approximately 29%. Immunotherapy seems to be an encouraging therapeutic strategy for EOC. Given the crucial role in the complicated interactions between tumor cells and other cells, the tumor microenvironment (TME) influences the response to immunotherapy. In this review, we discuss feasible strategies for EOC immunotherapy by exploiting the reciprocity of cancer cells and the constituents of the TME.
format Online
Article
Text
id pubmed-9630909
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96309092022-11-04 Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy Wang, Yusha Zhang, Lei Bai, Yun Wang, Li Ma, Xuelei Front Immunol Immunology Epithelial ovarian cancer (EOC) ranks as the second most common cause of gynecologic cancer death. The conventional treatment for patients with EOC is postoperative therapy along with platinum chemotherapy. However, a more efficient treatment regimen is of great need for these patients diagnosed with advanced disease (FIGO stages III–IV), whose survival is approximately 29%. Immunotherapy seems to be an encouraging therapeutic strategy for EOC. Given the crucial role in the complicated interactions between tumor cells and other cells, the tumor microenvironment (TME) influences the response to immunotherapy. In this review, we discuss feasible strategies for EOC immunotherapy by exploiting the reciprocity of cancer cells and the constituents of the TME. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9630909/ /pubmed/36341388 http://dx.doi.org/10.3389/fimmu.2022.1036298 Text en Copyright © 2022 Wang, Zhang, Bai, Wang and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Yusha
Zhang, Lei
Bai, Yun
Wang, Li
Ma, Xuelei
Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
title Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
title_full Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
title_fullStr Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
title_full_unstemmed Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
title_short Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
title_sort therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving pd-1/pd-l1 therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630909/
https://www.ncbi.nlm.nih.gov/pubmed/36341388
http://dx.doi.org/10.3389/fimmu.2022.1036298
work_keys_str_mv AT wangyusha therapeuticimplicationsofthetumormicroenvironmentinovariancancerpatientsreceivingpd1pdl1therapy
AT zhanglei therapeuticimplicationsofthetumormicroenvironmentinovariancancerpatientsreceivingpd1pdl1therapy
AT baiyun therapeuticimplicationsofthetumormicroenvironmentinovariancancerpatientsreceivingpd1pdl1therapy
AT wangli therapeuticimplicationsofthetumormicroenvironmentinovariancancerpatientsreceivingpd1pdl1therapy
AT maxuelei therapeuticimplicationsofthetumormicroenvironmentinovariancancerpatientsreceivingpd1pdl1therapy

Ejemplares similares